Cargando…

Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study

Beta2-adrenergic receptor (β2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of β2AR agonists and diabetic vascular complications. Using data from the Korean...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hee Jeong, Lee, Haekyung, Oh, Song Hee, Park, Suyeon, Jung, Kwang-Young, Kim, Hyoungnae, Kwon, Soon Hyo, Jeon, Jin Seok, Han, Dong Cheol, Noh, Hyunjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722988/
https://www.ncbi.nlm.nih.gov/pubmed/31370361
http://dx.doi.org/10.3390/jcm8081145
_version_ 1783448668922183680
author Lee, Hee Jeong
Lee, Haekyung
Oh, Song Hee
Park, Suyeon
Jung, Kwang-Young
Kim, Hyoungnae
Kwon, Soon Hyo
Jeon, Jin Seok
Han, Dong Cheol
Noh, Hyunjin
author_facet Lee, Hee Jeong
Lee, Haekyung
Oh, Song Hee
Park, Suyeon
Jung, Kwang-Young
Kim, Hyoungnae
Kwon, Soon Hyo
Jeon, Jin Seok
Han, Dong Cheol
Noh, Hyunjin
author_sort Lee, Hee Jeong
collection PubMed
description Beta2-adrenergic receptor (β2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of β2AR agonists and diabetic vascular complications. Using data from the Korean National Health Insurance Service, adults first diagnosed with diabetes in 2004 (n = 249,222) were followed up until 31 December 2015. Propensity score matching was performed between case and control groups (n = 5179 in each), and multivariate analysis was conducted. The β2AR agonist group was divided into quartiles according to the duration of β2AR agonist use. During the follow-up, the incidence of vascular complications gradually decreased as the duration of β2AR agonist administration increased. Multivariate analysis revealed that the hazard ratio for all composite vascular complications was 0.80 (95% CI, 0.75–0.86, p < 0.001) in the longest quartile of β2AR agonist use as compared with the control group after adjusting for confounding variables. The association between the duration of β2AR agonist use and the risk of each vascular complication including cerebrovascular, peripheral vascular, peripheral neural, renal, and ophthalmic complications was consistent, and the risks were significantly lower in the longest users than the control group. Long-term use of β2AR agonists may exert a protective effect against diabetic vascular complications.
format Online
Article
Text
id pubmed-6722988
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67229882019-09-10 Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study Lee, Hee Jeong Lee, Haekyung Oh, Song Hee Park, Suyeon Jung, Kwang-Young Kim, Hyoungnae Kwon, Soon Hyo Jeon, Jin Seok Han, Dong Cheol Noh, Hyunjin J Clin Med Article Beta2-adrenergic receptor (β2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of β2AR agonists and diabetic vascular complications. Using data from the Korean National Health Insurance Service, adults first diagnosed with diabetes in 2004 (n = 249,222) were followed up until 31 December 2015. Propensity score matching was performed between case and control groups (n = 5179 in each), and multivariate analysis was conducted. The β2AR agonist group was divided into quartiles according to the duration of β2AR agonist use. During the follow-up, the incidence of vascular complications gradually decreased as the duration of β2AR agonist administration increased. Multivariate analysis revealed that the hazard ratio for all composite vascular complications was 0.80 (95% CI, 0.75–0.86, p < 0.001) in the longest quartile of β2AR agonist use as compared with the control group after adjusting for confounding variables. The association between the duration of β2AR agonist use and the risk of each vascular complication including cerebrovascular, peripheral vascular, peripheral neural, renal, and ophthalmic complications was consistent, and the risks were significantly lower in the longest users than the control group. Long-term use of β2AR agonists may exert a protective effect against diabetic vascular complications. MDPI 2019-07-31 /pmc/articles/PMC6722988/ /pubmed/31370361 http://dx.doi.org/10.3390/jcm8081145 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Hee Jeong
Lee, Haekyung
Oh, Song Hee
Park, Suyeon
Jung, Kwang-Young
Kim, Hyoungnae
Kwon, Soon Hyo
Jeon, Jin Seok
Han, Dong Cheol
Noh, Hyunjin
Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study
title Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study
title_full Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study
title_fullStr Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study
title_full_unstemmed Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study
title_short Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study
title_sort association between beta2-adrenergic receptor agonists and the risk of vascular complications in diabetic patients: a population-based cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722988/
https://www.ncbi.nlm.nih.gov/pubmed/31370361
http://dx.doi.org/10.3390/jcm8081145
work_keys_str_mv AT leeheejeong associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT leehaekyung associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT ohsonghee associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT parksuyeon associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT jungkwangyoung associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT kimhyoungnae associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT kwonsoonhyo associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT jeonjinseok associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT handongcheol associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy
AT nohhyunjin associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy